MarginsXMarginsX
Home › Markets › Health Care › GNLX

Genelux Corporation (GNLX)

GNLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.92
+2.95% on the day
Market cap
$86.9M
Micro cap
Revenue · 2025
$8K
0.0% on 2024
Net income · 2025
-$32.1M
-401812.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/0001493152-26-011616-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGNLX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2023
SEC CIK0001231457
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$8K
Net income-$32.1M
Operating income-$33.2M
Net margin-401812.5%
Operating margin-415175.0%
Revenue growth0.0%
Cash$5.3M
Total assets$19.0M
P/E (computed)Net income was not positive
P/S (computed)10858.9×

Warning signs

Cash runway
4.4 months
$9.2M cash at June 30, 2026
Share count, 1 year
+19.8%
2025-08-04 to 2026-08-11 · +72.8% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
-$359K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-13
Cash and burn$9.2M cash; operating cash flow -$6.3M a quarter.Report 2026-06-30
Shares outstanding45,245,335 (2026-08-11); 37,773,443 a year earlier; 26,182,892 three years earlier.Cover page 2026-08-11
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-03-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWeinberg & Company, P.A., Los Angeles, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $359K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$9.5M-$6.4M$9.2MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$8.9M-$6.1M$9.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
Not filed-$9.2M-$6.2M$5.3MNo debt tags$8K10-K 2026-03-19
Q3 2025
2025-09-30
Not filed-$8.0M-$6.6M$4.7MNo debt tagsNeeds four quarters10-Q 2025-11-05
Q2 2025
2025-06-30
Not filed-$7.5M-$7.1M$6.5MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$7.5M-$5.4M$16.2MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
$0-$9.0M-$4.3M$8.6MNo debt tags$8K10-K 2026-03-19
Q3 2024
2024-09-30
$0-$6.5M-$5.7M$6.1MNo debt tags$8K10-Q 2025-11-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-19
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-06-22
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 363 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.8%
1 month-26.0%
3 months-29.1%
Year to date-57.2%
1 year-66.2%
From 52-week high-66.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NKTXNkarta Inc.$1.21+1.68%$86.8M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
RLYBRallybio Corporation$15.43-1.88%$86.4M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
PLYXPolaryx Therapeutics Inc.$1.67-6.99%$83.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier